Top

Published in:

01-07-2010 | Epidemiology

SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls

Authors: Zhanwei Wang, Yuanyuan Fu, Chunbo Tang, Su Lu, Wen-ming Chu

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

The SULT1A1 R213H polymorphism is suggested to be implicated in the development and progression of breast cancer. However, the published findings are inconsistent. We therefore performed a meta-analysis of 8,454 breast cancer cases and 11,800 controls from 14 published case–control studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association of the R213H polymorphism with breast cancer risk. Overall, our results suggested that there is no significant relationship between SULT1A1 R213H polymorphism and the risk of breast cancer. However, further ethnic population analysis revealed a significantly increased risk of breast cancer for HH allele carriers among Asians (for HH vs. RR: OR = 2.27, 95% CI = 1.11–4.63, P _{heterogeneity} = 0.63; for the recessive model: OR = 2.03, 95% CI = 1.00–4.41, P _{heterogeneity} = 0.62). Taken together, this meta-analysis suggests that the SULT1A1 R213H may be a low-penetrant risk factor for developing breast cancer in Asian population.

Coughtrie MW (2002) Sulfation through the looking glass–recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2:297–308CrossRefPubMed

Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298–304CrossRefPubMed

Glatt H (1997) Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. FASEB J 11:314–321PubMed

Glatt H (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129:141–170CrossRefPubMed

Falany JL, Falany CN (1996) Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 56:1551–1555PubMed

Raftogianis RB, Wood TC, Weinshilboum RM (1999) Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol 58:605–616CrossRefPubMed

Coughtrie MW, Gilissen RA, Shek B, Strange RC, Fryer AA, Jones PW, Bamber DE (1999) Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 337(Pt 1):45–49CrossRefPubMed

Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826PubMed

Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, Weinshilboum RM (2001) Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11:57–68CrossRefPubMed

10.

Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE et al (2000) Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60:6859–6863PubMed

11.

The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat

12.

Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR (2001) Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:89–94PubMed

13.

Yang G, Gao YT, Cai QY, Shu XO, Cheng JR, Zheng W (2005) Modifying effects of sulfotransferase 1A1 gene polymorphism on the association of breast cancer risk with body mass index or endogenous steroid hormones. Breast Cancer Res Treat 94:63–70CrossRefPubMed

14.

Tang D, Rundle A, Mooney L, Cho S, Schnabel F, Estabrook A, Kelly A, Levine R, Hibshoosh H, Perera F (2003) Sulfotransferase 1A1 (SULT1A1) polymorphism, PAH-DNA adduct levels in breast tissue and breast cancer risk in a case-control study. Breast Cancer Res Treat 78:217–222CrossRefPubMed

15.

Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K, Hirvonen A (2005) Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women. Pharmacogenet Genomics 15:749–752CrossRefPubMed

16.

Lilla C, Risch A, Kropp S, Chang-Claude J (2005) SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study. Breast Cancer Res 7:R229–R237CrossRefPubMed

17.

Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Wolf G, Wascher TC, Paulweber B, Weitzer W, Samonigg H (2004) Genetic variants of the sulfotransferase 1A1 and breast cancer risk. Breast Cancer Res Treat 87:19–22CrossRefPubMed

18.

Jerevall PL, Ahmadi A, Bergman M, Stal O, Wingren S (2005) Sulfotransferase 1A1 and risk of postmenopausal breast cancer. Anticancer Res 25:2515–2517PubMed

19.

Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, Liu F, Zheng F (2005) Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J 118:1507–1516PubMed

20.

Gulyaeva LF, Mikhailova ON, PustyInyak VO, Kim IV IV, Gerasimov AV, Krasilnikov SE, Filipenko ML, Pechkovsky EV (2008) Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 617:359–366CrossRefPubMed

21.

Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ et al (2005) Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1090–1095CrossRefPubMed

22.

Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, Wu PE, Shen CY (2005) Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 113:345–353CrossRefPubMed

23.

Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11:380–388CrossRefPubMed

24.

Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O’Brien TR et al (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300–310PubMed

25.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed

26.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

27.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed

28.

Dooley TP, Huang Z (1996) Genomic organization and DNA sequences of two human phenol sulfotransferase genes (STP1 and STP2) on the short arm of chromosome 16. Biochem Biophys Res Commun 228:134–140CrossRefPubMed

29.

Falany CN (1997) Enzymology of human cytosolic sulfotransferases. FASEB J 11:206–216PubMed

30.

Weinshilboum RM, Otterness DM, Aksoy IA, Wood TC, Her C, Raftogianis RB (1997) Sulfation and sulfotransferases 1: sulfotransferase molecular biology: cDNAs and genes. FASEB J 11:3–14PubMed

31.

Williams JA (2001) Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis 22:209–214CrossRefPubMed

32.

Adjei AA, Weinshilboum RM (2002) Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 292:402–408CrossRefPubMed

33.

Saintot M, Malaveille C, Hautefeuille A, Gerber M (2003) Interactions between genetic polymorphism of cytochrome P450–1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. Int J Cancer 107:652–657CrossRefPubMed

Title: SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls
Authors: Zhanwei Wang
Yuanyuan Fu
Chunbo Tang
Su Lu
Wen-ming Chu
Publication date: 01-07-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0648-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Adoptively transferred ex vivo expanded γδ-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger

In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up

Induction of the small heat shock protein αB-crystallin by genotoxic stress is mediated by p53 and p73

Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor α and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer